I guess the answer to my question is a NO, but with a glimmer of...

First 1070 Last

Share
Profile

Follow
Matters

170 Posts.

28

14/02/21

11:33

Post #: 50967298
Share

Originally posted by IronChef: ↑

Why are we onto -- allegedly -- IPO3? (We only have the company's word for that, and no underwriter is putting their name to this story yet.)
Have the reasons which caused the failure of IPO1 and 2, been addressed? Identified? Owned up to?
If you were an underwriter, with access to Google, would you return a call from people with this track record? Would you want this Board in charge of your fortunes? If you were an institutional shareholder in GMV, how would you feel right now?
This Board turned a 20c IPO on ASX into 3.9c and ultimately, delisting. So wouldn't a Nasdaq underwriter take a lot of convincing?
Has GMV's tech become any more appealing since IPO1 and 2 failed? Does technology mature like fine wine? Or does it simply become obsolete?
Does anyone seriously buy the notion that one death in China's government -- not known for giving individuals too much power -- would derail an entire medical approval process in the biggest market in the world?
I guess it's not *impossible* that a company which has never done what it's said it will do, could one day do what it says. But in 2021, when GMV describes its product, does it sound unique? Original? Disruptive?
The track record is all red flags and no product. Ginormous MOUs. Promised IPO in HK of subsidiary. The $22M deal with the company that promptly goes under. Death of a government scientist. And always opaque. Posters on HC have to become sleuths to try detect signs of life.
Like everyone, I can only hope.
And since I will be accused of down ramping -- which seems impossible when a company isn't listed -- I welcome all the positive facts that anyone can think of. But I emphasise: FACTS. Not fiction, not fantasy -- certainly not a world where other medical monitoring companies don't exist.

Expand

I guess the answer to my question is a NO, but with a glimmer of hope.
I do agree with most of you thoughts except the IPO2 failure... I actually believe the company's reasoning around the failed listing.

GMV Price at posting: 3.9¢ Sentiment: Sell Disclosure: Held
3 Upvote

0 Great analysis

Reply